在SHORT综合征和失控糖尿病中使用美特莱普
Emmanouil Korakas1,2, Aikaterini Kountouri1, Ignatios Ikonomidis3
12nd Propaedeutic Department of Internal Medicine, Research Unit and Diabetes Center, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 12462, Greece.
在患有SHORT综合征的患者中,美特利普丁有效地改善了血糖控制并降低了胰岛素需求,SHORT综合征是一种导致严重胰岛素抵抗的罕见疾病. 这表明metreleptin的存在.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 遗传学 是一个
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 肖特综合征是一种罕见的遗传性疾病,其特征是部分脂质变异,异形特征和严重的胰岛素抵抗.
- 患者经常出现胰岛素依赖性糖尿病,导致潜在的误诊.
- 在SHORT综合征中抗胰岛素的标准治疗可能不足.
研究的目的:
- 评估甲列平在治疗SHORT综合征患者严重胰岛素耐药性的疗效.
- 评估甲列普丁对血糖控制和胰岛素需求的影响.
- 为了探索metreleptin在非典型的脂质变现象型中的治疗潜力.
主要方法:
- 一名患有遗传确认的SHORT综合征 (PIK3R1变异) 的病例报告.
- 在治疗前,治疗期间和治疗后评估血糖控制 (HbA1c) 和胰岛素需求.
- 监测通常与脂质疏松相关的代谢并发症.
主要成果:
- 梅特利普丁的使用导致了血糖控制的快速和持续改善.
- 观察到胰岛素需求显著减少.
- 在治疗中断时发生了代谢恶化,并在重新开始时得到改善.
- 患者没有发生肝脏肥胖症或过高甘油三血症.
结论:
- 甲列列平是SHORT综合征中严重胰岛素抵抗的潜在治疗选择,即使没有经典的代谢并发症.
- 该药物在具有独特代谢特征的非典型脂质缩综合征中表现出有效性.
- 需要进一步的研究来确定甲列在治疗这种罕见疾病中的作用.
更多相关视频
10:09Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
10:31An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
